BEXIMCO PHARMA.GDR REGS 1 (F:R2WA) — Stock Price
BEXIMCO PHARMA.GDR REGS 1 (F:R2WA) is currently trading at €0.40 EUR, up 0.00% today. Over the past 52 weeks, shares have ranged between €0.40 and €0.40. This page tracks BEXIMCO PHARMA.GDR REGS 1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see R2WA market cap overview.
BEXIMCO PHARMA.GDR REGS 1 (R2WA) Stock Price Chart — Daily History & Trading Volume
The chart below tracks BEXIMCO PHARMA.GDR REGS 1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
BEXIMCO PHARMA.GDR REGS 1 Income Statement — Revenue, Profit & Earnings by Year
BEXIMCO PHARMA.GDR REGS 1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | €44.39 Billion | €39.27 Billion | €34.67 Billion | €29.49 Billion |
| Cost of Revenue | €24.76 Billion | €21.96 Billion | €18.85 Billion | €15.57 Billion |
| Gross Profit | €19.63 Billion | €17.30 Billion | €15.82 Billion | €13.92 Billion |
| Research & Development | €3.00 Million | €2.91 Million | €6.95 Million | €6.49 Million |
| SG&A | €5.60 Billion | €5.25 Billion | €4.49 Billion | €3.87 Billion |
| Total Operating Expenses | €35.80 Billion | €32.09 Billion | €27.82 Billion | €22.83 Billion |
| Operating Income | €8.59 Billion | €7.17 Billion | €6.85 Billion | €6.66 Billion |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €1.12 Billion | €1.24 Billion | €925.60 Million | €805.87 Million |
| Income Before Tax | €7.53 Billion | €6.07 Billion | €6.69 Billion | €6.38 Billion |
| Income Tax Expense | — | — | — | — |
| Net Income | €5.83 Billion | €4.61 Billion | €5.12 Billion | €5.13 Billion |
BEXIMCO PHARMA.GDR REGS 1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes BEXIMCO PHARMA.GDR REGS 1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Assets | €69.34 Billion | €69.16 Billion | €66.15 Billion | €52.25 Billion |
| Total Current Assets | €20.82 Billion | €20.88 Billion | €18.42 Billion | €13.77 Billion |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | €200.00 Million | — | — | — |
| Net Receivables | €3.46 Billion | €3.37 Billion | €2.96 Billion | €2.73 Billion |
| Inventory | €13.01 Billion | €12.95 Billion | €11.12 Billion | €7.80 Billion |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | €674.57 Million | €674.57 Million | €674.57 Million | €546.69 Million |
| Total Liabilities | €17.44 Billion | €21.54 Billion | €21.51 Billion | €14.88 Billion |
| Total Current Liabilities | €9.56 Billion | €13.27 Billion | €12.74 Billion | €9.35 Billion |
| Long-term Debt | €1.43 Billion | €2.16 Billion | €3.00 Billion | €972.70 Million |
| Net Debt | €4.71 Billion | €8.94 Billion | €10.58 Billion | €6.61 Billion |
| Total Stockholder Equity | €47.95 Billion | €43.68 Billion | €40.60 Billion | €37.03 Billion |
| Retained Earnings | €35.08 Billion | €30.81 Billion | €27.75 Billion | €24.18 Billion |
BEXIMCO PHARMA.GDR REGS 1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how BEXIMCO PHARMA.GDR REGS 1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating Cash Flow | €8.36 Billion | €6.08 Billion | €5.21 Billion |
| Capital Expenditures | €2.23 Billion | €2.71 Billion | €2.94 Billion |
| Free Cash Flow | €6.13 Billion | €3.37 Billion | €2.27 Billion |
| Investing Cash Flow | — | — | — |
| Financing Cash Flow | — | — | — |
| Dividends Paid | €1.59 Billion | €1.57 Billion | €1.62 Billion |
| Stock-Based Compensation | — | — | — |
| Depreciation | €1.99 Billion | €2.06 Billion | €1.67 Billion |
| Change in Cash | €-301.87 Million | €-92.80 Million | €149.35 Million |
BEXIMCO PHARMA.GDR REGS 1 Earnings History — EPS Actual vs. Analyst Estimates
Track BEXIMCO PHARMA.GDR REGS 1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Jan 27, 2026 | — | — | — |
| Nov 12, 2025 | — | — | — |
| May 06, 2025 | — | — | — |
| Jan 28, 2025 | — | — | — |
| Nov 04, 2024 | — | — | — |
| Mar 31, 2023 | 0.02 | — | — |
| Dec 31, 2022 | 0.03 | — | — |
| Sep 30, 2022 | 0.03 | — | — |